CVRx (NASDAQ:CVRX – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its peers? We will compare CVRx to similar companies based on the strength of its institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.
Profitability
This table compares CVRx and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CVRx | -88.28% | -208.45% | -55.42% |
| CVRx Competitors | -270.28% | -155.47% | -22.38% |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for CVRx and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CVRx | 1 | 5 | 1 | 0 | 2.00 |
| CVRx Competitors | 4311 | 10599 | 18393 | 838 | 2.46 |
CVRx currently has a consensus price target of $2.70, suggesting a potential upside of 340.46%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 22.19%. Given CVRx’s higher possible upside, research analysts clearly believe CVRx is more favorable than its peers.
Insider & Institutional Ownership
75.3% of CVRx shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 16.6% of CVRx shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares CVRx and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| CVRx | $60.33 million | -$53.31 million | -0.30 |
| CVRx Competitors | $1.89 billion | $135.83 million | 5.73 |
CVRx’s peers have higher revenue and earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
CVRx has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, CVRx’s peers have a beta of 2.58, suggesting that their average stock price is 158% more volatile than the S&P 500.
Summary
CVRx peers beat CVRx on 9 of the 13 factors compared.
About CVRx
CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.
